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Abstract

Pancreatic cancer is an aggressive cancer of the pancreas that has been shown to have
extremely low survival rates. It can be quite lethal because of its asymptomatic early stages and
inability to detect cancer at the cellular level. Once diagnosed, the cancer will have usually
spread or metastasized beyond surgical resection. Thus, research is focused on finding potential
biomarkers in tumor cell lines to help in earlier diagnosis of this disease leading to better
treatment options. Previous work using bioinformatics data suggest several cellular genes
including, CTHCR1, EPPK1, AHNAK2, and IGHG3, can be potential biomarkers for pancreatic
cancer. The goal of this project was to determine if protein expression of these genes was altered
in a variety of human pancreatic tumor cell lines. Protein isolation and quantification followed
by Western blot analysis was used. Our results showed a statistically significant increase of
CTHCR1 protein expression in SW 1990, a pancreatic tumor cell line, compared to the HPDE-6
control cell line. This data adds to the current evidence that CTHCR1 can act as a prospective
pancreatic cancer biomarker. There was also increased CTHCR1 protein expression in four other
human pancreatic tumorigenic cell lines, but they were not found statistically significant. EPPK1
was another potential biomarker studied; however, its large molecular weight was a challenge
and caused insufficient transfer of proteins. No bands were visualized.
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Introduction

The diagnosis of cancer is a life changing event. There are always many concerns and
questions such as: has it spread, what is the prognosis, what are possible therapies, and how long
is the life expectancy? Unfortunately, these questions usually have poor responses with regard to
pancreatic cancer. Pancreatic cancer is an aggressive cancer called a “silent killer.” It typically
has no symptoms in the early stages when surgical resection would be a preferred option.
Currently, diagnostic detection strategies are not specific or universal for all patients. By the
time of diagnosis, the cancer has usually metastasized beyond surgery, and other treatment
options still have low survival rates. Research suggests that there is significant need to discover
new specific pancreatic cancer biomarkers which are a measurable substance in an organism
whose presence is indicative of a certain disease or infection. New biomarkers specific to
pancreatic cancer would help in earlier diagnosis. Based on previous work by Goonesekere et al.
(2014), four genes, CTHCR1, EPPK1, AHNAK2, and IGHG3, have been suggested as potential
biomarkers for pancreatic cancer. The purpose of my thesis project is to attempt to determine if
these proteins can act as potential biomarkers. The project seeks to determine if the level of
protein expression of the four proteins is altered in several known human pancreatic tumor cell
lines and verify their status as novel biomarkers in pancreatic cancer. After determining protein
expression, we will be able to evaluate and better understand these genes as potential biomarkers
for pancreatic cancer. This thesis work will add to the current literature about pancreatic cancer
and potentially help in earlier diagnosis of this deadly disease leading to better prognosis, targets
for therapeutic intervention, and treatment options.
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Review of Literature
Pancreatic Cancer
The pancreas is a large organ deep in the abdomen with 2 glands: exocrine glands that
secrete digestive enzymes into the duodenum and endocrine cells that release hormones into the
blood stream. Exocrine glands and the duct where the enzymes are released make up more than
95% of the pancreas while endocrine cells make up less than 4% (American Cancer Society,
2015). The endocrine hormones produced, such as insulin and glucagon, are important in
controlling blood sugar levels. As reviewed in Singh et al. (2015), the majority of pancreatic
tumors come from exocrine cells. Cancer cells can be described as growing out of control and
invading other tissues due to their damaged DNA (American Cancer Society, 2015). The tumor
cells can grow around a population of cancer stem cells; these are cells that have the ability to
differentiate and self-renew. Even though not all tumors are cancerous, the exocrine and
endocrine cells of the pancreas have different types of tumors which have different treatment and
prognosis. Pancreatic ductal adenocarcinoma (PDAC) makes up approximately 90% of
pancreatic tumors which consequently starts in the ductal epithelium of the pancreas (Singh et
al., 2015). Other less common types of exocrine cells include adenosquamous carcinomas,
squamous cell carcinomas, signet ring cell carcinomas, undifferentiated carcinomas, and
undifferentiated carcinomas with giant cells (American Cancer Society, 2015). Solid
pseudopapillary neoplasms and ampullary cancer are other less common types, but more
commonly treatable. Endocrine tumors are rarer and are commonly known as neuroendocrine
tumors or islet cell tumors (American Cancer Society, 2015). They also generally have better
prognosis than exocrine tumors. Since pancreatic cancer is typically asymptomatic in early
stages and due to the metastasis of the disease, chances for cure at the time of diagnosis becomes
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very difficult (McKinney et al., 2011). Pancreatic cancer (PC) is one of the most aggressive types
of cancer in the United States with a median survival rate of less than six months according to
McKinney et al. (2011). It is the fourth most common cause of cancer death in North America
(Ouyang et al., 2000).
Pancreatic cancer is associated with an extremely poor prognosis due to the advanced
stage in which it is usually detected; many times the cancer has metastasized and is unable to be
resected surgically (Park et al., 2013). The location of the pancreas deep in the abdomen behind
the stomach eliminates the ability to palpate tumors, and almost acts as a hidden, sanctuary site.
Pancreatic cancer also can seem to come by “surprise” due to little to no known association with
family history or other diseases that increase the risk of PC (Chakraborty et al., 2011). Pancreatic
cancer is hereditarily complex. Age, however, is positively correlated and a majority of
pancreatic patients are over the age of sixty (Singh et al., 2015). Approximately 10% of PC
patients are thought to have a familial susceptibility with only a minority of these patients having
an inherited component and usually the responsible gene cannot be identified (Sclafani et al.,
2015). There are also risk factors such cigarette smoking and alcohol abuse that are associated
with the development of this cancer (Sclafani et al., 2015). Pancreatic cancer continues to be a
struggle for clinicians and scientists in diagnosis, and little progress has been made in the
treatment of the disease. There is a need to find the best route of care for each specific patient.
Diagnosis
Diagnosis has been difficult as not much progress has been made in biomarker
identification in pancreatic cancer. A biomarker is a measurable indicator of a specific biological
state, the presence or stage of a disease (Rifai et al., 2006). A biomarker can be the presence of a
specific gene or protein, and they can be used to screen for, diagnosis, or monitor the activity of
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diseases clinically. Clinically, the ultimate goal would be using a blood test or other readily
accessible biological fluids to test to see if a certain biomarker indicative of a disease is present.
These tests would be much faster and less invasive for patients and could be done at any time,
making a possibility of earlier diagnosis available. Biomarkers are also used in molecularly
targeted therapy (Rifai et al., 2006). However, their discoveries and implementations are
challenging and slow. Currently, there a few genes that are found mutated in pancreatic cancer.
Mutations in inherited genes such as BRCA2, p16, and the genes responsible for hereditary nonpoly colorectal cancer can increase a patient’s chances of developing PC (American Cancer
Society, 2015). Another non-invasive type of diagnosis is done through the detection of serum
markers in blood. CA19-9 is currently used and the most common to help detect pancreatic
cancer; however, this molecular biomarker has low specificity, is not expressed in high levels in
pancreatic cancer, and is also not constantly expressed in all PC patients (McKinney et al.,
2011). Some pancreatic cancers do not secrete CA 19-9 even at the later stages (Haab et al.,
2015). A variety of other serum markers have been reported to be elevated in pancreatic cancer;
however, they too have low sensitivity and specificity, and currently very few of these serum
markers have shown encouraging results (Bünger et al., 2011). Thus, there is great need for
identifying more specific markers that can detect pancreatic cancer while the disease is in its
early stages and that are found more consistently in PC patients (McKinney et al., 2011). The
heterogeneity of pancreatic cancer and range of mutations identified is likely to account for its
poor response to treatments and aggressiveness (Sclafani et al., 2015). The discovery of
biomarkers is needed to detect the full spectrum of pancreatic cancer cases (Haab et al., 2015).
Better PC screening would give patients earlier and better treatment options; therefore improving
survival ratings.
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Treatments
Treating pancreatic cancer is usually unsuccessful for the patient with only 10-15% of
patients amenable to surgery (Park et al., 2013). Other than tumor resection, most patients often
have to turn to more intensive treatments such as conventional radiation and chemotherapy,
which also can have adverse effects. The resistance to cytotoxic drugs and resection surgery
along with PC’s asymptomatic and metastatic nature make treatment extremely difficult leading
to high annual death rates. These annual mortality rates are even comparable to breast cancer
which is diagnosed at a rate 5 times greater than pancreatic cancer (Howlader et al., 2011). PC
patients have an approximate 5-year survival rate of less than 5% (Lee et al., 2010). In
summary, pancreatic cancer is one that that needs better methods of detection and screening
while the tumor is still at an early stage. Even though therapies have improved over the past ten
years, overall survival rates are still significantly low and new strategies are necessary.
Detection of potential new biomarkers
As stated previously, CA-19 is the biomarker currently used in pancreatic cancer
diagnosis and progression; however, its sensitivity to pancreatic cancer is not high (McKinney et
al., 2011). Therefore, research into finding other genes and markers of pancreatic cancer has
been a high priority. In a meta-analysis of microarray datasets by Goonesekere and colleagues in
2014, research focused on finding genes that were significantly upregulated in pancreatic cancer.
The study found four genes that were upregulated that were not previously associated or had a
known role with a cancer, specifically pancreatic cancer; AHNAK2, collagen triple helix repeat
containing-1 (CTHCR1), immunoglobulin heavy constant gamma-3 (IGHG3), and epiplakin
(EPPK1) were the four proteins. This thesis project was designed and based on this work.
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CTHCR1
The work by Goonesekere et al. (2014) suggested collagen triple helix repeat containing1 or CTHCR1 as a significantly up-regulated gene. CTHCR1 is a secreted protein approximately
30 kilo Daltons (kDa), and expressed at high levels during vascular remodeling and tissue repair
(Beachy et al., 2004). In a study performed by Tang et al. (2006), expression of CTHCR1 was
investigated in twenty solid cancer types through western blotting and CTHCR1 expression in
cancer cDNA arrays. Human CTHCR1 was detected and identified by western blot analysis in
melanoma cell lines, and not in normal melanocytes showing its potential as being expressed in
cancer but not normal cells. In the other part of the study by Tang et al. (2006), they used a
CTHCR1 specific gene probe to hybridize around 300 samples of cDNA from clinical tumor
biopsies along with a matching benign tumor biopsy. Results showed that CTHCR1 gene levels
were increased or upregulated (abnormally higher) in a majority of the cancers represented such
as cancers of the rectum, small intestine, colon, liver, lung, ovary, pancreas, and breast,
compared to the normal, control tissues (Tang et al., 2006). This can give optimism and perhaps
makes this gene an attractive option for developing a potentially new biomarker for various
cancers.
While CTHCR1 has been previously reported to be present in other carcinomas with poor
survival rates such as melanoma, breast cancer, colorectal, and gastric cancer, CTHCR1 has only
been associated with pancreatic cancer in a limited number of reports (reviewed in Goonesekere
et al., 2014). CTHCR1 also seems to play a role in tumors that are aggressive in nature. Mice
injected with CTHCR1 were found to have an increased number of tumor metastases. Results
also showed CTHCR1 expression was strongly detected in pancreatic adenocarcinoma cells
(Park et al., 2013) and that CTHCR1 expression enhances tumor progression, metastasis, tumor
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cell migration, and adhesion. According to Tang et al. (2006), in metastatic melanoma, CTHCR1
function is unclear, but results showed increased levels of tumor cell migration and tumor
invasion by regulating the surrounding environment. There are indications that CTHCR1 may
have a significant role in PC tumors, but it may not be required and all the functions are not
completely understood (Park et al., 2013). Based on this work, the current project evaluated if
increased CTHCR1 protein levels can serve as a potential biomarker for pancreatic cancer.
EPPK1
EPPK1, epiplakin, was another gene found to be significantly upregulated in the
microarray meta- analysis of pancreatic cancer by Goonesekere et al. (2014). Epiplakin is an
unusual protein compared to other members in the plakin family of cytolinker proteins that are
associated with the cytoskeleton and junctional complexes. EPPK1 may participate in supporting
intermediate filaments however specific function of this very large 552 kDa protein is not
precisely known. It has been found to be expressed in the pancreas and pancreatic ductal
adenocarcinomas and may be a useful biomarker for pancreatic cancer (Yoshida et al., 2008).
This increased expression in pancreatic tissue provides potential for this gene and protein
product to be evaluated as a potential biomarker of pancreatic cancer.
IGHG3
Immunoglobulin heavy constant gamma-3 (IGHG3) was another potential PC biomarker
cited by Goonesekere et al. (2014). This gene was significantly upregulated. It is known that
IGHG3 is a secreted antigen binding protein, but has no assigned function at this time
(Goonesekere et al., 2014). IGHG3 has not been directly associated with specific cancer
development or progression.
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AHNAK2
AHNAK2 is a large protein like EPPK1, with an estimated size of approximately 600
kDa. AHNAK2 is the second protein in the AHNAK family along with AHNAK. AHNAK2 was
found to be significantly upregulated gene in pancreatic cancer in the meta-analysis
(Goonesekere et al., 2014). Numerous studies have contributed to finding the function of
AHNAK2; however the specific function is unknown. The protein AHNAK has been associated
with forming part of multi-protein complexes, most likely acting as a structural support, which
AHNAK2 may share similarities with (Davis et al., 2014). AHNAK has been linked to several
muscular diseases and may be functional component to the costameric network (Goonesekere et
al., 2014).
There are limited studies linking the role of AHNAK2 in cancer (Davis et al. 2014);
however, there was discovery that AHNAK was significantly enriched in purified pseudopodia
of six different metastatic cancer cell lines and another study showed that knockdown of
AHNAK resulted in decreased migration and invasion of the cancer cells. In contrasting studies,
AHNAK was described as a protein that functions as a repressor of cancer, that is, it acts as a
tumor suppressor (Davis et al., 2014). While the exact function of AHNAK2 and AHNAK may
be unclear, they seem to have a large diversity of roles possibly pertaining to cancer, especially
pancreatic cancer. The meta-analysis suggested both IGHG3 and AHNAK2 need further
investigation to understand their association to pancreatic cancer, as their increased protein
expression could be a prospective marker for PC.
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Cell Lines
The current project was designed to evaluate levels of protein expression of these
potential biomarkers in a variety of tumor cell lines compared to a control cell line. We have
used immortal human pancreatic duct epithelial (HPDE) cells as a control pancreatic cell line.
HDPE cells demonstrate a similar gene expression pattern to normal, non-tumorigenic pancreatic
cells as compared to a cancerous cell line (Ouyang et al., 2000). This research proposes to use
the immortal human pancreatic duct epithelial (HPDE) cells as a control for our future studies on
pancreatic cancer.
Summary
Pancreatic cancer will continue to be a deadly diagnosis if we are unable to diagnose the
disease in its early stages. The current biomarkers and screening tools have not been successful
in detecting the tumors early enough for successful resection and recovery. Chemotherapy and
radiotherapy have also not guaranteed success. The necessity for new biomarkers or target genes
is ongoing. Previous studies have recognized CTHCR1, EPPK1, IGHG3, and AHNAK2 as
potential new biomarkers; these genes have been found to be expressed at higher levels in
pancreatic cancers. However, as there is still limited literature and knowledge, more
experimentation is needed. The goal of this thesis research project is to specifically quantify the
protein levels of the suggested genes to determine if the proteins are expressed at higher levels in
pancreatic cancer cell lines compared to normal pancreatic cells. This work can then add to the
current literature for finding new potential biomarkers for pancreatic cancer to improve early
detection of this lethal disease.
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Materials & Methods
Cell culture
A panel of six pancreatic tumor cell lines of human origin were obtained from the
American Type Culture Collection (ATCC). The cell lines included PANC-1, BxPc-3, AsPC-1,
Capan-2, HPAF-II, and CFPA-1. Human Pancreatic Duct Epithelial cells, HPDE-6, is a nontumorigenic cell line and was used as a control cell line. All cells were grown to confluence at
37°C in a humidified 5% CO2 incubator and were passaged every 2-4 days depending on cell
growth. Cell culture medium varied for all cell lines. HPDE-6 cells were grown in Keratinocyte
SFM supplemented with EGF and bovine pituitary extract and with 1% antibiotic-antimycotic.
ATCC-formulated RPMI-1640 Medium was used for AsPC-1 and BxPC-3. ATCC-formulated
Dulbecco’s Modified Eagle’s Medium was used for PANC-1. ATCC-formulated McCoy’s 5a
Medium was used for Capan-2. ATCC-formulated Eagle’s Minimum Essential Medium was
used for HPAF-II. ATCC-formulated Iscove’s Modified Dulbecco’s Medium was used for
CFPAC-1. ATCC-formulated Leibovitz’s L-15 Medium was used for SW 1990, and SW 1990
was the only cell line grown in a free gas exchange with atmospheric air incubator due to the L15 medium formulation. All cell line mediums had fetal bovine serum (FBS) to a final
concentration of 10% and 1% penicillin/streptomycin added.
Protein isolation and quantification
Total protein was harvested from a 100 mm tissue culture dish containing cells that were
80-100% confluent. Cell lysates were prepared according to the protocol provided from Santa
Cruz Biotechnology utilizing RIPA buffer (1X Lysis Buffer: 1X TBS, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 0.004% sodium azide). The RIPA buffer was supplemented
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with PMSF (2 mM), sodium orthovanadate (1 mM), and protease inhibitor cocktail. To
solubilize cellular proteins, 0.5 mL of complete RIPA buffer /100 mm dish was added with the
plates on ice. The plates were gently rocked while on ice for 15 minutes, and then a cell scraper
was used to remove the adherent cells which the resulting lysate was transferred into a microcentrifuge tube. The lysate was passed through a 25-gauge needle to shear the DNA, and then the
tube of lysate was incubated on ice for 30 minutes. After incubation, the cell lysate was
centrifuged at 10,000 rpm for 10 minutes at 4̊ C. The supernatant fluid, or whole cell lysate, was
then transferred to a new micro-centrifuge tube, and the pellet is discarded. The cell lysate was
subsequently quantified by the modified colorimetric Lowry assay (Bio-Rad) or stored at -80C
and quantified at a later date.
A modified Lowry Assay was used to quantify the proteins. Specific amino acids of a
protein interact with a dye producing a blue color which can be measured at 750nm. Absorbance
is positively correlated to the amount of protein present. To create a standard curve, known
dilutions of bovine serum albumin (BSA) from 0 to 2mg/ml were placed into a 96-well plate.
Five replicates of each standard concentration (0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0mg/ml) were
added to the plate. Additionally, a dilution of 1:4 or 1:5 of each cell lysate in RIPA buffer was
also included in the analysis. Five replicates of 5ul of each sample were added to the 96-well
plate. Next, reagents A and S (Bio-Rad) were combined and 25ul were added to each well. 200ul
of reagent B (Bio-Rad) was added into each well. The plate was then incubated at room
temperature for 15 minutes. During this time, any bubbles present were removed to prevent
inaccuracies when the absorbance was read. After 15 minutes, absorbance of the solutions in the
96 well-plate was read at the wavelength of 750 nm in a spectrophotometer. A linear regression
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line was generated using the SoftMax Pro 4.3.1 LS program. The correlation coefficient (R2) had
to be above 0.97 in order for the data to be used for further analysis.
Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis
After protein isolation and quantification, protein extracts from each cell line were
separated on a sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE). CTHCR1 with a
molecular weight of 25 kDa migrates farther through the gel than Epiplakin-1 which has
molecular weight of 552 kDa. This extremely large protein takes longer to pass through the gel.
To separate CTHCR1 protein from the cell lysate, 22 micrograms of protein were added to a
12% gel. Before loading the samples containing protein and 6X loading buffer, the protein
samples were denatured with heat for 5 minutes. The gel was run at room temperature for 55
minutes at 120 V in 1X Tris-glycine running buffer (25mM Tris base, 190mM glycine, 0.1%
SDS with pH around 8.3). To separate EPPK1 protein from the cell lysate, a 4-20% gradient
acrylamide gel was loaded with 30 micrograms of whole cell lysate (protein).The gel was run at
200V for two hours in 1X Tris-glycine running buffer at 4̊ C. After gel electrophoresis, the
proteins were transferred to a PVDF membrane using the iBlot 2 Dry Blotting System. The
membrane was then subjected to immunoblot analysis, described in the following section, or
stored at 4 degrees Celsius until analysis at a later time.
Immunoblot analysis
Immunoblot analysis was used to identify the target protein on the PDVF membrane.
Blocking the membrane prevents non-specific binding of antibodies; the primary antibody binds
to the specific target protein, while the specific secondary antibody binds to the primary
antibody. The secondary antibody has an enzyme conjugated to it which allows a detectable
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signal to be produced upon addition of substrate. In these experiments, the protein containing
PVDF membrane was incubated at room temperature in 5% milk in TBS blocking solution (5
grams per 100 ml of Tris Buffer Saline) for one hour with rocking followed by a TBS (Tris
Buffer Saline) wash for ten minutes, TBS-T (Tris Buffer Saline Tween20) wash for ten minutes,
and then TBS wash again for ten minutes. Next, the PVDF membrane was incubated with a
primary antibody targeted against the specific proteins (either anti-CTHCR1 or anti-EPPK1) at
various dilutions (1:50 – 1:300) in TBS-T or TBS buffer overnight at 4 degrees Celsius.
Following overnight incubation with rocking, blots were washed with TBS and TBS-T as stated
above, and subsequently probed with a secondary antibody in TBS-T or TBS buffer for one to
three hours gently rocking at room temperature. Following exposure to the secondary antibody,
the unbound secondary antibody was removed and a wash series of TBS and TBS-T as stated
previously was performed to the membranes.
Visualization of the Protein Bands
After the final wash, proteins were visualized using a chemiluminescence kit (Western
Lightning). Western Lighting is a non-radioactive, enzymatic reaction light-emitting system
designed to detect proteins immobilized on a membrane using an imaging system. Membranes
were incubated with gentle agitation for 30 to 40 seconds in equal parts of the Enhanced Luminol
Reagent and the Oxidizing Reagent. The membranes were then removed from the solution and
excess reagent was drained off. The STORM 860 phosphoimager was used immediately after to
scan the membranes. The blue fluorescence channel was used with normal sensitivity, pixel size
of 200 microns, and a PMT voltage of 800nm. After the membranes were scanned, they were
washed as stated previously in TBS and TBS-T, and then were ready to be stripped.
Visualization of bands used the Image Quant 5.2 program. Using the Image Quant 5.2 program,
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each specific protein band was individually selected and then the pixel volume was computed.
These volumes were entered into a spread sheet for analysis.
Actin Normalization
In order to normalize the concentrations of the targeted proteins from each of the blots,
each blot was stripped of its previous antibodies and reprobed with an antibody to actin, a protein
found in similar concentrations in most cells. The blots were stripped in stripping buffer (62.5
mM Tris-HCL H 6.8, 2% SDS, 100 mM 2-mercaptoethanol). Blots were incubated for 2 hours
with gentle agitation at 50̊ C. Then the membranes were washed in TBS-T for 5 minutes, 6 times.
The chemiluminescence kit (Western Lightning) was then used to make sure all bands had
disappeared. Then membranes were washed again in TBS-T as explained previously. At this
point, the blots were ready for reuse and incubated for 1 hour at room temperature with gentle
rocking in 5% milk TBS-T blocking solution followed by TBS wash for ten minutes, TBS-T
wash for ten minutes, and then TBS wash again for ten minutes. Blots were re-probed with antiactin primary antibody (Santa Cruz Biotechnology, 1:200) followed by a wash cycle and then a
complementary secondary antibody (Santa Cruz Biotechnology, 1:2,000), then visualization and
quantification as previously described.
Normalization is commonly used when measuring gene expression relative to a reference
sample such as actin. Actin is a “house-keeping gene” found in all cells and is required for basic
cellular functions. To evaluate fold change determination, the intensity values from CTHCR1
and corresponding actin intensity values were used. However, ratios of the intensity of the
protein CTHCR1 in the tumorigenic cell line compared to the control HDPE-6 intensity values
were first calculated. As there were two HPDE-6 intensity values from each gel, the values were
averaged and used to calculate the ratios. This was done for the CTHCR1 protein and for the
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actin protein. In order to normalize the values of the CTHCR1 to the level of actin, the
calculated ratio (tumorigenic cell line/HDPE-6) of the CTHCR1 protein was divided by the actin
ratio (tumorigenic cell line/HDPE-6) to determine the normalized fold change. If this ratio was
greater than one, there was overexpression of the protein in tumorigenic cell lines compared to
control, if the ratio was below one, tumorigenic cell lines showed decreased expression of
CTHCR1 compared to control.
Statistical Analysis
Quantification of bands calculated the expression of the target protein in tumorigenic cell
lines compared to control HDPE cells. In the analysis, three different samples from each cell line
were used in the analysis. As described above, the band intensity values were normalized with an
actin control and compared to the control cell line, HDPE. One way ANOVA with a two sided
Dunnett’s t-Test for post-hoc analysis was performed using the normalized fold values to
determine statistical significance where p<0.05 was considered statistically significant.
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Results
Currently, pancreatic cancer has a poor prognosis which could be explained by the
asymptomatic progression, late detection, and lack of effective treatments. This research was
based on an effort to provide new, potential biomarkers to help with earlier detection of
pancreatic cancer. Protein extracts from several human pancreatic cell lines were evaluated for
the expression of several potential protein biomarkers and compared to levels found in nontumorigenic pancreatic cell line that served as control. Western blot analysis was used in this
comparison. We were able to test two potential biomarkers: CTHCR1 and EPPK1.
CTHCR1
CTHCR1, collagen triple helix repeat containing-1, is a secreted protein approximately
30 kilo Daltons (kDa), and expressed at high levels during vascular remodeling and tissue repair
(Beachy et al., 2004). It was suggested as a significantly upregulated protein in work by
Goonesekere et al. (2014). This thesis work through western blot analysis found levels of
CTHCR1 to be significantly increased in one of the seven human pancreatic cancer cells that
were tested (Figure 1). The other six cell lines tested did not have any significant change in
levels of CTHCR1. Figure 1 is a representative gel for CTHCR1. The gel order is shown with
the molecular weight marker in the first lane, two unique samples of control HPDE-6, and one
sample from each of the 7 tumorigenic cell lines. Three separate gels with this order were run
and analyzed. The protein samples were each distinct on each gel, that is, each tumorigenic
sample was from 3 different cell passages of each cell line. There are non-specific bands
visualized on the blot as well. In the blot, SW 1990, in the far right lane, has the greatest amount
of CTHCR1 as quantified by measuring the band intensity using Image Quant software.
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Figure 1. Western blot analysis shows protein extracted from HPDE-6 cells (control) and one
individual, distinct sample from each of the seven pancreatic tumor cell lines. A band at the
expected region for CTHCR1, 26 kDa, can be seen in western blots. A molecular weight marker
is present on the left. This is a representative blot of the 3 replicates used in the analysis.

Figure 2 shows the previous blot after stripping it of anti-CTHCR1 antibodies and reprobing with anti-Actin antibody. Actin is a housekeeping gene involved in cell structure and
motility, and found in almost all cell types; it was used to determine a normalized fold change for
the CTHCR1 in tumorigenic cell lines compared to the HDPE-6 control cells. To make sure that
intensity values were different based on altered expression and not based on unequal amounts of
total protein loaded in each well, comparisons were made with actin since this protein is not
changed in the tumorigenic cell lines. The band intensity was used to normalize the results of
CTHCR1. Actin appeared in all the cell types and produced very consistent bands.

Figure 2. This is the corresponding blot from figure 1 after stripping CTHCR1 antibodies and
re-probing with anti-actin. Western blot analysis shows protein extracted from HPDE-6 cells
(control) and one individual, distinct sample from each of the 7 pancreatic tumor cell lines
express the protein, actin, which is expected. A molecular weight marker is on the left.
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Table 1 in Excel spreadsheet outlines the calculation process of determining the various
values of each blot. The volumes from each of the CTHCR1 bands and Actin bands were
determined by measuring the band intensity by Image Quant software. The two control HPDE-6
volumes were averaged from each study; the ratio of “Sample Vol. / Control Vol.” was
calculated between control and the samples from the tumorigenic cell lines by dividing the tumor
cell line volume by the average HDPE-6 volume. This was also performed for the actin protein.
The “Sample Vol. /Actin vol” column in the table shows the sample volume divided by the
corresponding actin volume ratio. “Normalized fold change” of the table shows the normalized
fold change by dividing the ratio of the sample volume/ actin volume ratio by same ratio of the
control HPDE-6 sample . This process was repeated for the three replicate blots.

Table 1. Analysis of CTHCR1 band intensities to calculate fold change of protein in tumorigenic
pancreatic cell lines compared to control cells.
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Cell line

Normalized fold
change ratios

HPDE6
HPDE6
HPDE6
HPDE6
HPDE6
HPDE6
AsPC1
AsPC1
AsPC1
BxPC3
BxPC3
BxPC3
CAPAN
CAPAN
CAPAN
CFPAC
CFPAC
CFPAC
HPAF-II
HPAF-II
Panc-1
Panc-1
Panc-1
SW-1990
SW-1990
SW-1990

1
1
1
1
1
1
1.026886443
0.516319976
1.1840629
0.868266588
0.759803007
0.278953255
0.868266588
1.452861313
0.84499545
0.635930922
1.650848583
1.675552035
1.423598247
0.989821384
0.90487261
1.367786293
1.003284923
2.401623713
2.050342668
1.001157473

Average of
Standard Error of
Normalized Ratios
the Mean
1

0

0.909089779

0.201558259

0.635674284

0.181087922

1.05537445

0.198856934

1.32077718

0.342497379

1.206709816

0.216888432

1.091981275

0.14079838

1.817707951

0.420680245

Table 2. CTHCR1 statistical analysis using One-way ANOVA.
Table 2 shows the calculated normalized ratios for all of the samples. The table also
shows the average of each cell line’s normalized ratios and the standard error of the mean of
each sample. For cell line HPAF-II, there are only two samples as there was an error in the
loading process and a third replicate was not available. Table 2 shows that pancreatic cell lines
AsPC1 and BxPC3 have decreased expression of the protein CTHCR1 as compared to the
control cell line HPDE-6. The other five pancreatic tumor cell lines (Capan-2, CFPAC-1, HPAF-
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II, PANC-1, and SW 1990) show increased expression compared to HPDE-6 cell lines. SW
1990 appears to have the greatest overexpression of CTHCR1, almost a two-fold increase. Table
3 below shows the results of the ANOVA multiple comparison Dunnett’s t-test. Only one cell
line showing statistical significance was SW 1990 with p value of 0.044, showing it was
significantly altered compared to HPDE-6. The other samples were not statistically significant
with values above 0.05. Figure 3 below shows the results from Table 2 and Table 3 in graphical
format.

Dunnett t (2-sided)

a

Variable

Control

AsPC1
BxPC3
Capan-2
CFPAC-1
HPAF-II
PANC-1
SW 1990

HPDE6
HPDE6
HPDE6
HPDE6
HPDE6
HPDE6
HPDE6

Mean
Difference
-.09091
-.36433
.05537
.32078
.20671
.09198
*

Std. Error

Significance

0.271644176
0.271644176
0.271644176
0.271644176
0.313667677
0.271644176
0.271644176

1.000
0.698
1.000
0.800
0.986
1.000

0.044*
.81771
*. The mean difference is significant at the 0.05 level. *. Significant when below 0.05
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.

Table 3. ANOVA Dunnett’s t-test results for CTHCR1. Compares protein expression of the panel
of human pancreatic tumor cell lines to the control cell line. SW 1990 shows statistical
significance with a value below 0.05.
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Figure 3. CTHCR1 expression levels in a panel of human pancreatic tumor cell lines. Each cell
line was normalized with actin and formulated a normalized ratio of sample volume over control
volume. Error bars represent the standard error of the mean for each cell line. HDPE-6 is the
control cell line. Ratios above 1.0 show increased expression compared to control and those
below 1.0 show decreased levels of this protein. SW 1990, indicated with an asterisk, is the only
statistically significant cell line with increased CTHCR1 expression.

In Figure 3, the horizontal axis is the specific cell line and the vertical axis is each cell
lines’ average of normalized fold change ratios (From Table 2). Error bars represent the standard
error of the mean of each cell line. The HPDE-6 is the control cell line with a baseline ratio of 1.
AsPC-1 and BxPC-3 show decreased expression of CTHCR1 while the other cell lines have
increased expression. However, these alterations in expression did not prove statistically
significant except for SW 1990. SW 1990 has an almost two- fold increase of expression of
CTHCR1 over the control HPDE-6 (Figure 3).
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EPPK1
EPPK1 was another protein found to be significantly upregulated in the previous analysis
performed by Goonesekere et al. (2014). It is a larger in molecular weight at 552 kDa and is
associated with the cytoskeleton proteins. Western blot analysis on the protein EPPK1 was
attempted and it proved difficult to obtain results. With EPPK1’s molecular weight at 552 kDa,
results from gel after transfer showed that the protein did not fully transfer from the gel to the
membrane. As shown in Figure 4 there was a significant amount of protein left in the wells of the
gel where EPPK1 and higher molecular weight proteins would be located. The darker coloration
of purple indicates more protein.

Figure 4. A gel for EPPK1 after SDS-Page and transfer of proteins to membrane stained in
Coomassie Blue stain and dried showing a significant amount of protein left over in the wells of
the gel.

Incomplete transfer leads to less protein on the membrane. When the membranes were
probed with anti-EPPK1 antibodies, no bands were visualized as shown in Figure 5. In one
instance, there was an experiment when a faint band could be seen near the top of the membrane
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as seen in Figure 6 that was suspected to be EPPK1; however, the band located in this region of
the membrane was never visualized more than once even though several modifications of
methods were attempted such as increasing the transfer time, increasing the intensity of voltage,
varying the dilutions of primary and secondary antibodies and the medium of
diluent. Additionally, the amount of protein loaded onto the gel was also increased from 22ug to
50ug; however, EPPK1 could not be visualized more than one time.

Figure 5. Example of a Western blot with no visible bands in the EPPK1 region probed with
anti-EPPK1 antibody. A molecular weight protein is seen on the far left and in the 6th lane.
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Figure 6. Western blot analysis shows HPDE-6 (on left) and BxPC-3 (on right) cell lines showed
protein expression of EPPK1. Molecular weight marker is on the left. The bands were detected
at the expected region for Epiplakin-1, 552 kDa.

IGHG3 and AHNAK2
Due to restricted time and focus on completing CTHCR1 and EPPK1 analysis, evaluation
of IGHG3 and AHNAK2 protein levels was not performed at this time. CTHCR1 and EPPK1
required an extensive amount of time to optimize the western blot methods.
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Discussion
This thesis project was based on a previous meta-analysis study to suggest several
cellular genes including, CTHCR1, EPPK1, AHNAK2, and IGHG3, as potential biomarkers for
pancreatic cancer (Goonesekere et al., 2014). Our goal was to determine if protein expression of
these genes was altered in a variety of human pancreatic tumor cell lines. Significant changes in
protein expression in tumor cell lines compared to control could disclose a new potential
biomarker to help in earlier diagnosis of pancreatic cancer leading to better treatment options.
Cell culture, protein isolation and quantification followed by Western blot analysis was
performed. The results showed that there was a significant increase, nearly two-fold, in
expression of CTHCR1 in the tumorigenic cell line SW 1990 (Figure 3). The human pancreatic
tumorigenic cell line, SW 1990, was obtained from a 56 year old male who had adenocarcinoma
of the pancreas derived from the spleen metastatic site. The cell line obtained from the American
Tissue Cell Collection is epithelial and adherent in nature and did not require 5% CO2 for
growth, unlike the other cell lines used in this study. There was also a trend of increased
expression in CTHCR1 in four other pancreatic tumor cell lines (Table 2), there was no
statistically significant increase in protein expression. In contrast, two pancreatic tumor cell lines
that had decreased expression of the protein CTHCR-1, however, these levels were also not
statistically significant.
CTHCR1, also known as collagen triple helix containing 1, has been associated with
multiple other cancers other than pancreatic cancer. CTHCR1 is a secreted protein around 30
kDa and its function is related to tissue repair (Goonesekere et al., 2014). A prior study looked at
CTHCR1’s presence and role in melanoma and other human solid cancer cells. The potential
biomarker was found to be expressed at the mRNA and protein levels in melanoma cancer cells
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(Tang et al., 2006). Although the study did not find a significant function of CTHCR1, CTHCR1
was found at much higher levels in invasive melanoma compared to a noninvasive type which
suggests CTHCR1 may play a role in migration and metastasis. The same study by Tang et al.
found that the majority of 19 human solid cancers had increased expression of CTHCR1, such as
cancers of the pancreas, rectum, colon, small intestine, cervix, thyroid gland, lung, ovary, and
breast; however, testis, prostate, and trachea tumors were the exception and showed no
significant increase (Tang et al., 2006). These results add to our finding that CTHCR1 was
upregulated in the pancreatic tumor cell line compared to control. The meta-analysis study
showed that CTHCR1 was greater than a 1,000 fold increase in protein expression (Goonesekere
et al., 2014). While in our hands, there was only a two-fold significance of CTHCR1 in a
cancerous cell line to control there was still an increase and thus suggests that CTHCR1 can still
be a potential biomarker with future research.
Challenges faced in the research
Western blot analysis can be a challenging technique. The CTHCR1 and EPPK1 studies
took much longer than expected. Optimizing the western blot protocol to visual bands was a long
process and took many different trials and variations. There were 40 total western blots run over
the span of doing research with several blots divided off into small segments meaning even more
trials. For CTHCR1, the amount of isolated total protein loaded onto the gel ranged from 22 to
35 micrograms (ug) of protein with the attempt to get a stronger, visible signal. For EPPK1, total
isolated protein ranged from 22 ug to 50 ug. Transfer time of the protein was also adjusted many
times. A wet transfer method of transfer was first used, then the iBlot system was used; this
system was much more efficient not only in the time of transfer, but the amount of protein that
was transferred. The temperature conditions, dilution solution such as TBS, TBS-T, or 5% milk
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in TBS, or 5% milk in TBS-T, and length of time of the primary and secondary antibody
incubations were also modified. CTHCR1 ranged ratios of primary from 1:100 to 1:300 and
secondary from 1:2,000 to 1:15,000. EPPK ranged ratios of primary from 1:100 to 1:500 and
secondary from 1:1,500 to 1:10,000. Western blot analysis is time-consuming considering that
each blot takes two to three days and then if stripping and reprobing the blot, another two days
must be added. Western blot analysis takes time, persistence, and longevity to optimize the
protocol.
Future Suggested Work
Several areas of future work can be expanded from this thesis. More trials of western
blots looking at CTHCR1 could be obtained for a stronger statistical analysis. In this current
study, there were only three replicates. Other than SW 1990 showing significant expression the
protein CTHCR1, tumorigenic cell line, BxPC3, appeared to have only half the expression of the
control cell line. This was not found significant at this time; however, with more trials, it may be
found significant. Another way to enhance this study would be to remove the background bands.
Several of the blots of CTHCR1 show excess signal of non-specific bands even after numerous
runs. The multiple bands can come from excess of primary or secondary antibodies; multiple
optimization experiments to adjust concentrations would need to occur. In future studies, more
time could be allowed for this. More optimization experiments to find the lowest concentration
of isolated protein needed to detect a band would also be constructive.
EPPK1 was very challenging to visualize. EPPK1 was one of the higher molecular
weight proteins at 552 kDa along with AHNAK2 at approximately 600 kDa. Incomplete transfer
of the protein from the gel to the membrane would be an area to focus on in future work. Even
though 17 western blots were run for EPPK1, there was only one faint band visualized once.
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Unfortunately, this visualization was never repeated. This is a very small victory, but shows
there is room for more improvement with more time.
Due to time restrictions and the difficulties of visualizing CTHCR1 and EPPK1, IGHG3
and AHNAK2 were not evaluated using western blot analysis at this time. Our lab has frozen
down samples of the pancreatic tumor cell lines and control cell line and stored the isolated
protein samples. An antibody used to detect IGHG3 has been purchased and is ready to use.
IGHG3 has a smaller molecular weight, similar to CTHCR1, and with more time, IGHG3 should
be easily visualized on western blots. In contrast, I do expect the AHNAK2 will be difficult to
transfer similar to EPPK1 due to its high molecular weight of approximately 600 to 630 kDa.
This research will hopefully be continued in the future.
Another aspect of future work would be comparing the results of protein expression to
the results from the RNA expression study performed. As mentioned earlier, this research was
part of a two-part study with half looking at expression of the target gene at the RNA level
through qPCR and the other half at the protein level through western blot analysis. Comparing
these results from both parts of research could add supporting evidence that one of the four genes
could be a potential biomarker for pancreatic cancer.
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Conclusions
Pancreatic cancer is commonly discovered and diagnosed at a later stage when the cancer
has spread or metastasized beyond surgical resection. Even with traditional therapies, a patient
with advanced stages of PC has a very poor prognosis and life expectancy. PC is asymptomatic
in early stages; finding a new, alternative way to detect pancreatic cancer early on is inevitable
for better treatment options. Therefore, research has been focused on finding new biomarkers
which are specific indicators of a certain disease. The current project was based on work using
bioinformatics data by Goonesekere et al. (2014). The investigators suggested CTHCR1, EPPK1,
AHNAK2, and IGHG3 as potential biomarkers for pancreatic cancer. The goal of this thesis was
to determine if protein expression of these genes was altered in a variety of human pancreatic
tumor cell lines through western blot analysis. CTHCR1 results showed a significant increase of
protein expression in SW 1990, a pancreatic tumor cell line, compared to the HPDE-6 control
cell line. This suggests that this human tumorigenic cell line had an increased level of CTHCR1
protein when compared to amounts found in a cell line that appeared to be normal. This data
adds to the current that evidence that CTHCR1 can act as a prospective pancreatic cancer
biomarker. There was also increased CTHCR1 protein expression in four other human pancreatic
tumorigenic cell lines, but they were not found statistically significant. EPPK1 was another
potential biomarker mentioned significantly upregulated in a previous study (Goonesekere et al.,
2014); however, its large molecular weight was a challenge and caused insufficient transfer of
proteins. Several adjustments were made, but unfortunately no bands indicating present proteins
were visualized. More time and research will be needed to look more into EPPK1, AHNAK2,
and IGHG3, and also in repeating CTHCR1. In conclusion, these new findings about CTHCR1
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will add to the literature of potential biomarkers for pancreatic cancer which in the future will
lead to earlier detection and much better prognosis.
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